335 related articles for article (PubMed ID: 12835883)
1. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
[TBL] [Abstract][Full Text] [Related]
2. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
3. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial.
Kneebone A; Mameghan H; Bolin T; Berry M; Turner S; Kearsley J; Graham P; Fisher R; Delaney G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1088-97. PubMed ID: 15519779
[TBL] [Abstract][Full Text] [Related]
4. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
5. [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy].
Freund U; Schölmerich J; Siems H; Kluge F; Schäfer HE; Wannenmacher M
Strahlenther Onkol; 1987 Oct; 163(10):678-80. PubMed ID: 3313776
[TBL] [Abstract][Full Text] [Related]
6. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
[TBL] [Abstract][Full Text] [Related]
7. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
8. Can we decrease the acute proctitis in prostate cancer patients using hyaluronic acid during radiation therapy: a prospective historically controlled clinical study.
Stefanelli A; Pascale G; Rainieri E; Ursino S; Colella M; Zini G; Berretta M; Fiorica F
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):639-45. PubMed ID: 22774405
[TBL] [Abstract][Full Text] [Related]
9. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
10. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
11. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
12. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis.
O'Brien PC; Franklin CI; Dear KB; Hamilton CC; Poulsen M; Joseph DJ; Spry N; Denham JW
Radiother Oncol; 1997 Nov; 45(2):117-23. PubMed ID: 9424000
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer.
Hille A; Schmidberger H; Hermann RM; Christiansen H; Saile B; Pradier O; Hess CF
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1488-93. PubMed ID: 16137837
[TBL] [Abstract][Full Text] [Related]
14. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group.
O'Brien PC; Franklin CI; Poulsen MG; Joseph DJ; Spry NS; Denham JW
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):442-9. PubMed ID: 12243820
[TBL] [Abstract][Full Text] [Related]
15. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
17. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
18. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
19. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
